VivoSeq
Other

Pervasive Developmental Disorder

8

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Pervasive Developmental Disorder is an early-stage landscape with 8 programs across 5 companies. The most active players are Otsuka, Teva, Promius Pharma, LLC. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

92/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Otsuka logo

Otsuka

1 program

Phase 3Teva logo

Teva

1 program

ApprovedP

Promius Pharma, LLC

1 program

PreclinicalNovartis logo

Novartis

1 program

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

13

clinical trials

Completed11 · 85%
Terminated1 · 8%
Unknown status1 · 8%

Clinical Trials

Trial Activity

13 trials

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
Completed·FForest Laboratories·Phase 2·NCT01592747·479 enrolled
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Completed·IIndiana University·Phase 3·NCT00870727·33 enrolled
Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders
Completed·National Institute of Mental Health (NIMH)·N/A·NCT00025779·60 enrolled
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00261508·80 enrolled
RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
Completed·YYale University·N/A·NCT00080145·124 enrolled
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Completed·YYale University·Phase 4·NCT01238575·62 enrolled
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Completed·MMassachusetts General Hospital·Phase 3·NCT01302964·30 enrolled
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Completed·FForest Laboratories·Phase 2·NCT01592786·906 enrolled
A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.
Completed·IIndiana University School of Medicine·Phase 2·NCT00198055·25 enrolled
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
Completed·—·Phase 1·NCT00147394·100 enrolled
Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)
Completed·—·Phase 1/2·NCT00166595·100 enrolled
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Terminated·FForest Laboratories·Phase 2·NCT01592773·747 enrolled
Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)
Unknown status·HHadassah Medical Organization·Phase 1/2·NCT00318162·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)